Clinical Trial Update: AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating CK-4021586 in heart failure with preserved ejection fraction to assess safety and tolerability; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• CK-4021586

Snippet

Sponsor: Cytokinetics | Conditions: Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Status: RECRUITING